文献速递血管炎其他结缔组织病

炎症性肠病患者中的IgA血管炎:TNF-α抑制剂作用的新见解

IgA vasculitis in patients with inflammatory bowel disease: new insights into the role of TNF-α blockers.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

该回顾性多中心队列纳入43例炎症性肠病(IBD)合并IgA血管炎(IgAV)患者,88%的IgAV发生于IBD诊断之后(中位间隔9.2年),其中74%在IgAV诊断时正接受抗TNF-α治疗。停用抗TNF-α与血管炎缓解相关但增加IBD复发风险,继续用药则与IBD缓解相关但血管炎复发风险升高。

要点

  • IBD患者中IgAV多在抗TNF-α治疗期间出现,中位用药31.5个月。
  • 停用抗TNF-α后无IgAV复发,但33%出现IBD复发或并发症。
  • 重新启用抗TNF-α后67%再现IgAV复发。

核心结论

  • TNF-α抑制剂可能促进IBD患者发生IgA血管炎。
  • 停用抗TNF-α与血管炎缓解相关但增加IBD复发风险,继续用药则与IBD缓解相关但血管炎复发风险升高。

研究设计与样本

  • 通过GETAID和FVSG网络进行的回顾性分析,共纳入43例IBD合并IgAV患者。
  • 使用标准化病例报告表收集IBD和IgAV特征。

主要发现

  • IBD先于IgAV发生者38例(88%),中位间隔9.2年(IQR 5.4-15.4)。
  • 在38例中,IgAV诊断时5例(13%)IBD活动,28例(74%)正接受抗TNF-α治疗,中位疗程31.5个月(IQR 19-56)。
  • IgAV主要表现:紫癜100%(全部患者),关节受累20/35(57%),肾脏受累15/35(43%),胃肠道受累11/35(31%)。
  • IgAV治疗:糖皮质激素25例(66%),秋水仙碱6例(16%),环磷酰胺6例(16%);抗TNF-α停用15/28例(54%)。
  • 停用抗TNF-α者无IgAV复发,继续用药者复发率23%;停用后5例(33%)出现IBD复发或并发症,继续用药者1例(8%);重新启用抗TNF-α者6例(40%),其中4例(67%)IgAV复发。

临床怎么用

  • IBD患者接受抗TNF-α治疗期间需警惕IgAV发生。
  • 发生IgAV时是否停用抗TNF-α需权衡血管炎缓解与IBD复发风险。

局限性

  • 回顾性研究设计。
  • 样本量较小(43例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The association of IgA vasculitis (IgAV) and IBD is rarely described, mainly during anti-TNF-α therapy. We aimed to describe the association of IgAV and IBD. METHODS: We retrospectively analysed the association of IgAV and IBD through the implication of the GETAID and FVSG networks. Characteristics of IBD and IgAV were collected using a standardized case report form. RESULTS: Forty-three cases were included. IBD [mainly Crohn's disease (CD) in 58%] preceded IgAV in 38 (88%), with median interval of 9.2 (IQR 5.4-15.4) years. In these 38 patients, at IgAV diagnosis, five (13%) had active IBD and 28 (74%) were treated with anti-TNF-α for a median duration of 31.5 (IQR 19-56) months. Main IgAV manifestations were purpura all patients (100%), joints in 20/35 (57%), renal in 15/35 (43%) and gastrointestinal in 11/35 (31%) involvement. IgAV was treated with glucocorticoids in 25 (66%), colchicine in six (16%), CYC in six (16%) and anti-TNF-α were discontinued in 15/28 (54%). No IgAV relapse occurred when TNF-α blockers were stopped, vs 23% in patients pursuing it. Conversely, five (33%) had IBD flare or complication after anti-TNF-α cessation vs one (8%) in those continuing biologics. Anti-TNF-α were resumed in six (40%), with subsequent IgAV relapse in four (67%). CONCLUSIONS: This large cohort suggests that TNF-α blockers may promote the onset of IgAV in IBD. Discontinuation of anti-TNF-α was associated with vasculitis remission but increased risk of IBD relapses, whereas continuation of anti-TNF-α was associated with IBD remission but vasculitis relapse.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Rasmussen C, Abitbol V, El Karoui K, et al. IgA vasculitis in patients with inflammatory bowel disease: new insights into the role of TNF-α blockers. Rheumatology (Oxford). 2022. PMID: 34427590. doi:10.1093/rheumatology/keab662

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。